BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baier PC, Weinhold SL, Huth V, Gottwald B, Ferstl R, Hinze-Selch D. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). Brain 2008;131:2734-41. [PMID: 18718966 DOI: 10.1093/brain/awn193] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Bayard S, Plazzi G, Poli F, Serra L, Ferri R, Dauvilliers Y. Olfactory dysfunction in narcolepsy with cataplexy. Sleep Medicine 2010;11:876-81. [DOI: 10.1016/j.sleep.2010.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
2 Calva CB, Fadel JR. Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction. Brain Res 2020;1731:145921. [PMID: 30148983 DOI: 10.1016/j.brainres.2018.08.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
3 Prud'homme MJ, Lacroix MC, Badonnel K, Gougis S, Baly C, Salesse R, Caillol M. Nutritional status modulates behavioural and olfactory bulb Fos responses to isoamyl acetate or food odour in rats: roles of orexins and leptin. Neuroscience 2009;162:1287-98. [PMID: 19477242 DOI: 10.1016/j.neuroscience.2009.05.043] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
4 Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep 2015;7:51-61. [PMID: 26045680 DOI: 10.2147/NSS.S56077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
5 Majid H, Hirshkowitz M. Therapeutics of Narcolepsy. Sleep Medicine Clinics 2010;5:659-73. [DOI: 10.1016/j.jsmc.2010.08.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
6 Siegel JM. Rapid Eye Movement Sleep. Principles and Practice of Sleep Medicine. Elsevier; 2017. pp. 78-95.e6. [DOI: 10.1016/b978-0-323-24288-2.00008-8] [Cited by in Crossref: 13] [Article Influence: 2.6] [Reference Citation Analysis]
7 Lammers GJ. Intranasal hypocretin-1: making sense of scents? Sleep Med 2011;12:939-40. [PMID: 22136855 DOI: 10.1016/j.sleep.2011.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
8 Weinhold SL, Göder R, Baier PC. Pathway and Effect of Intranasal Orexin. In: Sakurai T, Pandi-perumal S, Monti JM, editors. Orexin and Sleep. Cham: Springer International Publishing; 2015. pp. 339-51. [DOI: 10.1007/978-3-319-23078-8_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
10 Calva CB, Fayyaz H, Fadel JR. Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats. Front Aging Neurosci 2019;11:362. [PMID: 32038222 DOI: 10.3389/fnagi.2019.00362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 2018;143:155-70. [PMID: 30449731 DOI: 10.1016/j.brainresbull.2018.10.009] [Cited by in Crossref: 157] [Cited by in F6Publishing: 133] [Article Influence: 39.3] [Reference Citation Analysis]
12 Chapman CD, Frey WH 2nd, Craft S, Danielyan L, Hallschmid M, Schiöth HB, Benedict C. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res 2013;30:2475-84. [PMID: 23135822 DOI: 10.1007/s11095-012-0915-1] [Cited by in Crossref: 164] [Cited by in F6Publishing: 149] [Article Influence: 16.4] [Reference Citation Analysis]
13 Palouzier-Paulignan B, Lacroix MC, Aimé P, Baly C, Caillol M, Congar P, Julliard AK, Tucker K, Fadool DA. Olfaction under metabolic influences. Chem Senses 2012;37:769-97. [PMID: 22832483 DOI: 10.1093/chemse/bjs059] [Cited by in Crossref: 183] [Cited by in F6Publishing: 170] [Article Influence: 18.3] [Reference Citation Analysis]
14 Zaghloul H, Pallayova M, Al-Nuaimi O, Hovis KR, Taheri S. Association between diabetes mellitus and olfactory dysfunction: current perspectives and future directions. Diabet Med 2018;35:41-52. [PMID: 29108100 DOI: 10.1111/dme.13542] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
15 Dhuria SV, Hanson LR, Frey WH. Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous System. J Pharmacol Exp Ther 2008;328:312-20. [DOI: 10.1124/jpet.108.145565] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
16 Lopez R, Dauvilliers Y. Pharmacotherapy options for cataplexy. Expert Opin Pharmacother 2013;14:895-903. [PMID: 23521426 DOI: 10.1517/14656566.2013.783021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
17 Li J, Hu Z, de Lecea L. The hypocretins/orexins: integrators of multiple physiological functions. Br J Pharmacol 2014;171:332-50. [PMID: 24102345 DOI: 10.1111/bph.12415] [Cited by in Crossref: 153] [Cited by in F6Publishing: 141] [Article Influence: 19.1] [Reference Citation Analysis]
18 Buskova J, Klaschka J, Sonka K, Nevsimalova S. Olfactory dysfunction in narcolepsy with and without cataplexy. Sleep Med 2010;11:558-61. [PMID: 20513636 DOI: 10.1016/j.sleep.2010.01.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
19 Samaridou E, Alonso MJ. Nose-to-brain peptide delivery - The potential of nanotechnology. Bioorg Med Chem 2018;26:2888-905. [PMID: 29170026 DOI: 10.1016/j.bmc.2017.11.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
20 Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res 2021. [PMID: 33491126 DOI: 10.1007/s13346-020-00891-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
21 De la Herrán-arita AK, Drucker-colín R. Models for narcolepsy with cataplexy drug discovery. Expert Opinion on Drug Discovery 2012;7:155-64. [DOI: 10.1517/17460441.2012.651454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Erichsen JM, Calva CB, Reagan LP, Fadel JR. Intranasal insulin and orexins to treat age-related cognitive decline. Physiol Behav 2021;234:113370. [PMID: 33621561 DOI: 10.1016/j.physbeh.2021.113370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Liu X. Clinical trials of intranasal delivery for treating neurological disorders--a critical review. Expert Opin Drug Deliv 2011;8:1681-90. [PMID: 22097907 DOI: 10.1517/17425247.2011.633508] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
24 Truzzi GM, Cremaschi RC, Coelho FM. Human hypocretin-deficient narcolepsy - aberrant food choice due to impaired taste? Sleep Sci 2017;10:78-9. [PMID: 28966744 DOI: 10.5935/1984-0063.20170014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Cochen De Cock V, Dauvilliers Y. Current and future therapeutic approaches in narcolepsy. Future Neurology 2011;6:771-82. [DOI: 10.2217/fnl.11.48] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Arias-Carrión O, Murillo-Rodríguez E. Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats. PLoS One 2014;9:e95342. [PMID: 24736646 DOI: 10.1371/journal.pone.0095342] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
27 Truzzi GM, Naufel MF, Tufik S, Coelho FM. Narcolepsy: the impact of aging, hypocretin deficiency, and years of formal education in olfactory function and abdominal obesity. Arq Neuropsiquiatr 2021;79:808-15. [PMID: 34495122 DOI: 10.1590/0004-282X-anp-2020-0352] [Reference Citation Analysis]
28 Dhuria SV, Fine JM, Bingham D, Svitak AL, Burns RB, Baillargeon AM, Panter SS, Kazi AN, Frey WH, Hanson LR. Food consumption and activity levels increase in rats following intranasal Hypocretin-1. Neuroscience Letters 2016;627:155-9. [DOI: 10.1016/j.neulet.2016.05.053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
29 Mahowald MW, Schenck CH. The REM sleep behavior disorder odyssey. Sleep Med Rev 2009;13:381-4. [PMID: 19394252 DOI: 10.1016/j.smrv.2009.02.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
30 Khan AR, Liu M, Khan MW, Zhai G. Progress in brain targeting drug delivery system by nasal route. J Control Release 2017;268:364-89. [PMID: 28887135 DOI: 10.1016/j.jconrel.2017.09.001] [Cited by in Crossref: 127] [Cited by in F6Publishing: 106] [Article Influence: 25.4] [Reference Citation Analysis]
31 Ghielmini E, Poryazova R, Baumann CR, Bassetti CL. Sleepiness at the Time of Testing Impairs Olfactory Performance. Eur Neurol 2013;69:58-64. [DOI: 10.1159/000337449] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
32 Lebedev AA, Bessolova YN, Efimov NS, Bychkov ER, Droblenkov AV, Shabanov PD. Role of orexin peptide system in emotional overeating induced by brain reward stimulation in fed rats. RRP 2020;6:81-91. [DOI: 10.3897/rrpharmacology.6.52180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev 2015;35:152-97. [PMID: 25044006 DOI: 10.1002/med.21326] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
34 Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. International Journal of Pharmaceutics 2009;379:146-57. [DOI: 10.1016/j.ijpharm.2009.06.019] [Cited by in Crossref: 381] [Cited by in F6Publishing: 331] [Article Influence: 29.3] [Reference Citation Analysis]
35 Lochhead JJ, Thorne RG. Intranasal Drug Delivery to the Brain. In: Hammarlund-udenaes M, de Lange EC, Thorne RG, editors. Drug Delivery to the Brain. New York: Springer; 2014. pp. 401-31. [DOI: 10.1007/978-1-4614-9105-7_14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
36 Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, Göder R, Baier PC. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res 2014;262:8-13. [PMID: 24406723 DOI: 10.1016/j.bbr.2013.12.045] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 7.5] [Reference Citation Analysis]
37 Chase MH. A unified survival theory of the functioning of the hypocretinergic system. J Appl Physiol (1985) 2013;115:954-71. [PMID: 23640599 DOI: 10.1152/japplphysiol.00700.2012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
38 Staton CD, Yaeger JDW, Khalid D, Haroun F, Fernandez BS, Fernandez JS, Summers BK, Summers TR, Sathyanesan M, Newton SS, Summers CH. Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression. Neuropharmacology 2018;143:79-94. [PMID: 30240784 DOI: 10.1016/j.neuropharm.2018.09.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
39 Baier PC, Hallschmid M, Seeck-Hirschner M, Weinhold SL, Burkert S, Diessner N, Göder R, Aldenhoff JB, Hinze-Selch D. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med 2011;12:941-6. [PMID: 22036605 DOI: 10.1016/j.sleep.2011.06.015] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
40 Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 2009;32:993-8. [PMID: 19725250 DOI: 10.1093/sleep/32.8.993] [Cited by in Crossref: 154] [Cited by in F6Publishing: 123] [Article Influence: 11.8] [Reference Citation Analysis]
41 Bershad EM, Urfy MZ, Calvillo E, Tang R, Cajavilca C, Lee AG, Venkatasubba Rao CP, Suarez JI, Chen D. Marked olfactory impairment in idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2014;85:959-64. [PMID: 24474821 DOI: 10.1136/jnnp-2013-307232] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
42 Adeghate E. Orexins: tissue localization, functions, and its relation to insulin secretion and diabetes mellitus. Vitam Horm. 2012;89:111-133. [PMID: 22640611 DOI: 10.1016/b978-0-12-394623-2.00007-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
43 de Martin Truzzi G, Naufel MF, Tufik S, Coelho FM. The influence of narcolepsy on olfactory function: a review. Sleep Med 2020;72:75-81. [PMID: 32554327 DOI: 10.1016/j.sleep.2020.03.023] [Reference Citation Analysis]
44 Aly AE, Waszczak BL. Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier. Expert Opin Drug Deliv 2015;12:1923-41. [PMID: 26289676 DOI: 10.1517/17425247.2015.1069815] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
45 Pasban-Aliabadi H, Esmaeili-Mahani S, Abbasnejad M. Orexin-A Protects Human Neuroblastoma SH-SY5Y Cells Against 6-Hydroxydopamine-Induced Neurotoxicity: Involvement of PKC and PI3K Signaling Pathways. Rejuvenation Res 2017;20:125-33. [PMID: 27814668 DOI: 10.1089/rej.2016.1836] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
46 Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 2009;98:2501-15. [PMID: 19025760 DOI: 10.1002/jps.21604] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 6.2] [Reference Citation Analysis]
47 Thannickal TC. A decade of hypocretin/orexin: Accomplishments in sleep medicine. Sleep Medicine Reviews 2009;13:5-8. [DOI: 10.1016/j.smrv.2008.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
48 Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy—clinical aspects, pathophysiology and management strategy. Nat Rev Neurol 2014;10:386-95. [DOI: 10.1038/nrneurol.2014.97] [Cited by in Crossref: 103] [Cited by in F6Publishing: 77] [Article Influence: 12.9] [Reference Citation Analysis]
49 Fukuda M, Kanazawa T, Iioka S, Oguma T, Iwasa R, Masuoka S, Suzuki N, Kosuge Y, Suzuki T. Quantitative analysis of inulin distribution in the brain focused on nose-to-brain route via olfactory epithelium by reverse esophageal cannulation. J Control Release 2021;332:493-501. [PMID: 33647429 DOI: 10.1016/j.jconrel.2021.02.024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]